Cardio-Oncology is affiliated with the International Cardio-Oncology Society (ICOS).
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. Howe...